SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure amid broader market volatility, with the community actively debating whether the stock is a long-term value opportunity or a sinking asset due to execution risks and high valuation concerns. Investors are closely monitoring the stock's technical support levels as bearish sentiment surges over delivery performance and potential capital rotation into other ventures.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing significant volatility and fragmented sentiment as market participants brace for an upcoming press conference regarding geopolitical tensions and the conflict with Iran. The community is actively debating the reliability of ceasefire rumors while monitoring price action for signs of an institutional 'rug pull' or potential market-moving headlines.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust is experiencing heavy volatility as investors weigh conflicting reports of ceasefire negotiations against ongoing military tensions in the Middle East, leading to intense debate among market participants about whether current price action reflects genuine growth or orchestrated market manipulation. The community is actively parsing news regarding geopolitical deadlines and oil price shifts while attempting to navigate algorithmic swings driven by uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the geopolitical volatility surrounding the escalating conflict with Iran, highlighted by threats to regional energy infrastructure and ongoing tensions over the Strait of Hormuz. Investors and political commentators remain sharply divided, with discussions centered on the potential market impact of these developments, skepticism toward official press briefings, and the broader implications for the U.S. domestic economy and national security.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited ($MGRT) is trending as retail traders monitor its volatile price action and frequent trading halts, often comparing its movement to other low-float Chinese IPOs. The community remains deeply divided, with some betting on a potential squeeze and parabolic gains, while many others warn of a typical 'pump and dump' scam that frequently characterizes similar recent market entrants.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors cheer the company's strategic pivot into AI infrastructure and recent high-profile production orders for its ultra-high-power testing systems. The community is heavily focused on the company's role as a critical bottleneck gatekeeper for reliability in the hyperscale data center supply chain, fueling bullish sentiment around upcoming earnings and guidance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading amidst intense market volatility as investors weigh the impact of an escalating geopolitical conflict in the Strait of Hormuz against ongoing, often contradictory, ceasefire reports. Community discourse is heavily polarized, with many market participants expressing frustration over potential market manipulation and the unpredictable nature of administration rhetoric regarding war timelines.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently experiencing significant downward pressure, with shares recently hitting fresh all-time lows amid ongoing frustration regarding manufacturing scale-up delays and missed quarterly milestones. While the community remains polarized, with some bulls pointing to a significant cash position and potential upside from future customer purchase orders, many traders are vocal about the lack of consistent execution and are actively discussing the possibility of further price declines toward the mid-four-dollar range.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense volatility and aggressive trading as investors debate whether recent price action is a fundamental valuation correction driven by AI-related substrate demand or a speculative bubble prone to a sharp reversal. The community remains deeply divided, with many traders monitoring for a potential dilution event while others emphasize the company's critical role in the photonics supply chain.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

Buttcoin

Buttcoin is gaining significant community attention as a long-standing memecoin project that proponents are positioning as a humorous, culturally driven alternative to Bitcoin. Investors are actively discussing its historical roots, speculative long-term potential, and its role as a narrative-heavy asset within the broader meme-driven crypto sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Key PointsMichael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026...

Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one ha...

Michael Raab Sells 41,666 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the sale, the chief executive officer owned...

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the sale, the chief executive officer...

Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan

Ardelyx (NASDAQ:ARDX) executives outlined commercial momentum for IBSRELA and XPHOZAH, key investment priorities for 2026, and development plans for a chronic idiopathic constipation (CIC) expansion...

Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX

Vanguard Group Inc. grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 14.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving Average - What's Next?

Ardelyx (NASDAQ:ARDX) Stock Price Crosses Below Two Hundred Day Moving Average - Here's What Happened...

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Key PointsMichael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share...

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity...

<ul class="summary-bullets"><li>Director David Mott bought 333,333 shares at a weighted average price of $5.84, lifting his stake to more than 3.3 million shares.</li><li>The insider buy followed a mixed Q4 earnings report in which revenue rose to $125.2 million, beating expectations, while earnings remained flat.</li><li>Ibsrela drove the revenue beat, offsetting softer Xphozah sales, and the company guided for Ibsrela revenue of $410 million to $430 million in 2026.</li></ul>Ardelyx shares jumped more than 5% overnight after a board director made a sizable open-market purchase, adding fuel to growing investor confidence in Ibsrela, the company’s flagship constipation drug.<a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> rose 0.4% on Monday after tumbling 15% on Friday, when the company reported no earnings for the fourth quarter (Q4).<h2 class="st-heading-2">Ardelyx Director Buys 333K Shares In Open Market</h2>According to a new regulatory filing, David Mott, a director at Ardelyx, purchased 333,333 shares of the company’s stock on Friday at a weighted average price of $5.84 per share.The filing shows the purchase was made in multiple open-market transactions, with prices ranging from $5.67 to $6.00. Following the buy, Mott holds over 3.3 million Ardelyx shares.&nbsp;<h2 class="st-heading-2">Ibsrela Drives Q4 Revenue Beat</h2>The insider buy followed Ardelyx’s Q4 earnings report, where revenue rose to $125.2 million, up from $116.1 million a year earlier. The result topped Wall Street expectations of about $119.4 million.The company said the increase was driven largely by higher adoption of Ibsrela, which is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Growth in Ibsrela helped offset softer sales from Xphozah, Ardelyx’s drug for lowering phosphate levels in patients with chronic kidney disease on dialysis.Earnings per share came in at $0.0, compared with $0.02 in the year-ago quarter and slightly below expectations of $0.01.<h2 class="st-heading-2">Strong 2026 Outlook Anchored By Ibsrela</h2>Alongside the results, Ardelyx expects Ibsrela revenue of $410 million to $430 million in 2026, representing growth of at least 50% from 2025 levels. The company cited improvements in prescribing across target healthcare providers, higher patient engagement, and stronger prescription pull-through. For Xphozah, the company forecast 2026 revenue of $110 million to $120 million, up from $103.6 million in 2025.Ardelyx also said it is running additional programs to evaluate Ibsrela in chronic idiopathic constipation and continues to advance its experimental asset RDX10531 across multiple potential indications.<h2 class="st-heading-2">Analysts Reaffirm Bullish Views</h2>On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. Meanwhile, H.C. Wainwright raised its target by 80% to $18 from $10 on Friday, while reiterating a ‘Buy’ rating.H.C. Wainwright said it was encouraged by Ardelyx securing a new U.S. patent extending to November 2042, covering oral formulations of Tenapor, including Ibsrela and Xphozah. Ardelyx has since confirmed that both drugs are now listed in the FDA’s Orange Book, marking a step that strengthens intellectual property protection.CEO Mike Raab previously said the listing was “an important step in extending protections for our portfolio of first-in-class medicines.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for ARDX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rdx_ss_png_9ca239304b.webp" alt="rdx ss.png" width="968" height="140"><figcaption>ARDX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “Maybe retailers will realize now’s the time to buy. Nice buy by mott ”<stembedurl>https://stocktwits.com/mktfixer/message/645684167</stembedurl>Another user said, “Always nice seeing Mr.Mott’s investing in the company. Clearly, he’s in it to win it. He knows what he owns and how the current strategy will be a success. So swell! “<stembedurl>https://stocktwits.com/imlivinit/message/645684336</stembedurl>ARDX stock has declined 1.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Equity

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARDX News

ARDXArdelyx Inc